SELLAS Life Sciences stock has doubled this year as investors focus on encouraging trial data in acute myeloid leukemia. Its Phase 2 SLS009 study showed a 58% response rate in certain AML patients, while the Phase 3 REGAL trial is evaluating whether galinpepimut-S can improve overall survival, driving strong retail optimism.